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Abstract In humans, the divalent metal ion transporter-1 (DMT1) mediates the transport of
ferrous iron across the apical membrane of enterocytes. Hence, its inhibition could be beneficial for
the treatment of iron overload disorders. Here we characterize the interaction of aromatic bis-
isothiourea-substituted compounds with human DMT1 and its prokaryotic homologue EcoDMT.
Both transporters are inhibited by a common competitive mechanism with potencies in the low
micromolar range. The crystal structure of EcoDMT in complex with a brominated derivative
defines the binding of the inhibitor to an extracellular pocket of the transporter in direct contact
with residues of the metal ion coordination site, thereby interfering with substrate loading and
locking the transporter in its outward-facing state. Mutagenesis and structure-activity relationships
further support the observed interaction mode and reveal species-dependent differences between
pro- and eukaryotic transporters. Together, our data provide the first detailed mechanistic insight
into the pharmacology of SLC11/NRAMP transporters.
Introduction
Hereditary hemochromatosis (HH) is a multigenic iron overload disorder that results from the exces-
sive absorption of iron in the intestine (Pietrangelo, 2010; Yen et al., 2006). In the absence of a
regulated mechanism for its excretion, excessive iron can lead to significant tissue damage in the
heart, liver, endocrine glands and other organs (Pietrangelo, 2010; Yen et al., 2006). The most
prevalent form of HH is associated with the upregulation of the iron transport protein DMT1 (or
SLC11A2) (Byrnes et al., 2002; Fleming et al., 1999; Rolfs et al., 2002; Stuart, 2003), which facili-
tates the uptake of ferrous iron (Fe2+) across the apical membrane of enterocytes and whose expres-
sion is regulated on a transcriptional level (Fleming et al., 1997; Gunshin et al., 1997;
Shawki et al., 2012). The current strategy to treat hemochromatosis is phlebotomy, which can have
unwanted side-effects and which is not an option in cases of secondary hemochromatosis, such as
thalassemia, since patients in this case are also anemic (Brissot et al., 2011; Gattermann, 2009). A
potential alternative strategy to counteract excessive iron uptake would be the interference of trans-
port by inhibition of DMT1 (Crielaard et al., 2017). Due to the accessibility of the transporter from
the apical side, inhibition could proceed from the intestinal lumen by compounds that would not
have to cross the membrane.
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DMT1 is a member of the conserved SLC11/NRAMP family, which is expressed in all kingdoms of
life and which constitutes transporters for transition metals such as Fe2+ and Mn2+ (Nevo and Nel-
son, 2006; Shawki et al., 2012). The transport properties of DMT1 have been characterized in detail
by employing electrophysiology and cellular uptake studies, which demonstrated the broad selectiv-
ity for transition metals and the discrimination of alkaline earth metal ions such as calcium. The same
studies also revealed the symport of H+, which serves as energy source for concentrating the sub-
strate in the cell (Bozzi et al., 2016a; Mackenzie et al., 2006; Pujol-Gime´nez et al., 2017;
Tandy et al., 2000).
Insight into the structural basis of transport was provided from different prokaryotic homologues.
Crystal structures and functional characterization of these prokaryotic transporters uncovered the
general architecture of the protein family and defined the conformational transitions during trans-
port (Bozzi et al., 2016b; Bozzi et al., 2019; Ehrnstorfer et al., 2014; Ehrnstorfer et al., 2017).
Additionally, these studies defined the chemistry of metal ion coordination and provided insight into
the mechanism of proton coupling. SLC11 transporters are monomers and their fold resembles the
general organization of a branch of the APC (amino acid-polyamine-cation) superfamily containing
transporters for amino acids and glucose (Forrest and Rudnick, 2009; Yamashita et al., 2005).
These proteins consist of two topologically related units of five transmembrane (TM) helices each,
which are arranged within the membrane with opposite orientation. The substrate binding site is
located in the center of the protein formed by residues in unwound regions of the pseudo-symmetry
related a-helices 1 and 6. In metal ion transporters of the SLC11 family the binding-site contains
side-chains of conserved aspartate and asparagine residues located on a1 which are directly
involved in ion interactions and a methionine residue on a6, which acts as soft ligand that is capable
of coordinating transition metal ions but not Ca2+ (Bozzi et al., 2016a; Ehrnstorfer et al., 2014).
Large aqueous cavities that alternately provide access to the substrate binding site from opposite
sides of the membrane are found in the inward-facing conformation of the transporter from Staphy-
lococcus capitis (ScaDMT) (Ehrnstorfer et al., 2014), the outward-facing conformation of the trans-
porter from Eremococcus coleocola (EcoDMT) (Ehrnstorfer et al., 2017) and in multiple structures
of the transporter from Deinococcus radiodurans (DraDMT), which occupy different states on the
transport cycle (Bozzi et al., 2016b; Bozzi et al., 2019).
Although different structural and functional studies have revealed the mechanism of transition
metal ion transport, the pharmacology of SLC11 transporters is still poorly characterized, which has
thus far prevented the therapeutic exploration of DMT1 inhibition. The most potent inhibitors of
DMT1 identified by screening of large synthetic libraries (Buckett and Wessling-Resnick, 2009;
Cadieux et al., 2012; Montalbetti et al., 2015; Zhang et al., 2012) are aromatic bis-isothiourea
substituted compounds, which display IC50 values in the low micromolar range and presumably work
by a competitive mechanism (Montalbetti et al., 2015; Zhang et al., 2012). Whereas studies in a
rat model of iron hyperabsorption showed reduced iron uptake in the presence of these inhibitors,
underlining the general validity of the approach (Zhang et al., 2012), their binding mode to the pro-
tein has remained elusive. To overcome this bottleneck in our mechanistic understanding of inhibi-
tion and aid the improvement of inhibitors by structure-based design, we have here characterized
the detailed interactions between aromatic bis-isothiourea based compounds and their derivatives
with human DMT1 and its prokaryotic homologue EcoDMT. Our study combines chemical synthesis
with data from X-ray crystallography, isothermal titration calorimetry, in vitro transport and cellular
uptake studies to demonstrate that the characterized inhibitors interact with pro- and eukaryotic
transporters in a similar manner although with species-dependent differences. These compounds
bind deep in a funnel-shaped cavity leading to the metal ion coordination site with one of the iso-
thiourea groups directly interacting with residues of this site thus interfering with substrate loading
and locking the transporter in its outward-facing conformation.
Results
Functional characterization of the interaction of bis-isothiourea
substituted aromatic compounds with human DMT1
To characterize the inhibition mechanism of human DMT1 and its prokaryotic homologue EcoDMT
by bis-isothiourea-containing aromatic compounds, we have synthesized seven molecules of this
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substance class. These include five compounds carrying two isothiourea moieties for which we have
varied the aromatic scaffolds (i.e. a brominated dibenzofuran and a single phenyl ring with different
substituents) to investigate the influence of their respective size and geometry on inhibition
(Figure 1A, Appendix 1). For simplicity, we termed the tri-methyl and tri-ethyl substituted benzyl
bis-isothiourea compounds TMBIT and TEBIT, respectively, and the dibenzofuran-based compound
Br-DBFIT. Br-DBFIT, TMBIT and its derivatives were previously described as inhibitors of DMT1
(Zhang et al., 2012). To ease the identification of benzyl bis-isothiourea compounds in inhibitor
complexes by X-ray crystallography, we have also synthesized the brominated derivatives Br-BIT and
oBr-BIT. Additionally, we have synthesized two variants of the inhibitor oBr-BIT where we have
replaced one or both isothiourea moieties by bulkier thio-2-imidazoline groups. All molecules are
water-soluble and thus poorly membrane-permeable with both basic isothiourea groups being
Figure 1. Chemical structure of compounds and their inhibition of human DMT1. (A) Chemical structures of compounds used in this work. Their
synthesis is described in detail in Appendix 1. Abbreviations are indicated. (B) IC50 values determined by measuring radioactive
55Fe2+ transport (at 1
mM) into HEK293 cells stably expressing hDMT1. Data from brominated compounds are colored in lilac and data from compounds with modified
isothiourea groups in violet. Values show averages of 6–8 biological replicates, errors are s.d.
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. Characterization of compounds.
Figure supplement 2. Inhibition of hDMT1.
Figure supplement 3. Transport kinetics of hDMT1 at different inhibitor concentrations.
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predominantly charged under physiological conditions (pKa = 8.5–9.5 as measured in a titration of
TMBIT and Br-BIT, Figure 1—figure supplement 1A). We first tested the activity of all compounds
on human DMT1 (hDMT1) by measuring radioactive 55Fe2+ transport into HEK293 cells stably
expressing the protein. When assayed at a free Fe2+ concentration of 1 mM, all compounds inhibit
metal ion uptake in a dose-dependent manner with IC50 values in the micromolar range (Figure 1B,
Figure 1—figure supplement 2). The most potent compounds TEBIT and TMBIT display IC50 values
of 0.27 mM and 0.35 mM, respectively, latter being in close quantitative agreement with a previous
measurement using a calcein-based fluorescence assay (IC50 = 0.29 mM) (Figure 1B, Figure 1—fig-
ure supplement 2B,C) (Zhang et al., 2012). In comparison, the larger values of Br-BIT (4.66 mM) and
oBr-BIT (2.3 mM) indicate an equivalent interaction with somewhat lower affinity and the dibenzofu-
ran compound Br-DBFIT (1.24 mM) is in our hands less potent than previously reported (Figure 1B,
Figure 1—figure supplement 2A,D and E) (Zhang et al., 2012). To rule out that the observed activ-
ity would be due to chelation of divalent metal ions, we performed isothermal titration calorimetry
measurements. Upon titrating MnCl2 to either TMBIT or Br-BIT, we did not detect any pronounced
response that would indicate specific binding (Figure 1—figure supplement 1B), emphasizing that
the inhibition of 55Fe2+ transport is caused by the specific interactions of either compound with
hDMT1. We next investigated the role of the positively charged isothiourea groups for protein inter-
actions by comparing the potency of oBr-BIT with its variants where one or two of the moieties were
replaced. In case of the replacement of a single isothiourea group, we were able to measure a four-
fold reduced potency of 8.13 mM whereas a much stronger reduction (IC50 = 161 mM) was obtained
for a compound where both isothioureas were modified (Figure 1—figure supplement 2F,G).
Together these results underline the importance of the isothiourea moieties for specific protein inter-
actions. To further characterize the mode of inhibition, we studied the effect of different extracellular
inhibitor concentrations on the kinetics of iron transport (Figure 1—figure supplement 3). In the
absence of inhibitors, the transport rate at different 55Fe2+ concentrations can be fitted to a Michae-
lis-Menten equation with KM values of 2.6 mM to 4.4 mM and vmax values of 2.7 to 6.1 pmol min
 1
well 1, which is in general agreement with previously reported values (Gunshin et al., 1997;
Mackenzie et al., 2006; Pujol-Gime´nez et al., 2017). At increasing inhibitor concentrations, we
observed in all tested cases a pronounced increase of the apparent KM whereas the apparent vmax
values decreased only slightly (Figure 1—figure supplement 3, Table 1). These results suggest that
the compounds act by a predominant competitive mechanism. When fitting the data to a mixed
enzyme inhibition model the resulting equilibrium constants are in the micromolar range with inhibi-
tors binding with much higher affinity to the substrate-free transporter (Table 1). Taken together,
our data confirm the activity of aromatic isothiourea-based compounds as competitive inhibitors of
hDMT1 with potencies in the low micromolar range. As all compounds are positively charged and
thus membrane-impermeable, the binding site of the inhibitor is expected to be accessible from the
extracellular side.
Functional characterization of the interaction with EcoDMT
After the characterization of hDMT1 inhibition, we have studied the properties of different bis-iso-
thiourea compounds on the prokaryotic SLC11 homologue EcoDMT, which catalyzes H+-coupled
Mn2+ symport and whose structure was determined in an outward-facing conformation by X-ray crys-
tallography (Ehrnstorfer et al., 2017). Due to the insufficient solubility of the dibenzofuran-based
inhibitor Br-DBFIT and TEBIT for experiments with EcoDMT, we restricted this analysis to the benzyl
bis-isothiourea compounds TMBIT, Br-BIT and oBr-BIT. To characterize EcoDMT-mediated transport,
we have reconstituted the purified protein into liposomes and used a fluorescence-based in-vitro
assay (Figure 2—figure supplement 1A). In these proteoliposomes, EcoDMT is incorporated in
inside-out and outside-out orientations at about equal ratios (Figure 2—figure supplement 1B).
Concentration-dependent Mn2+ uptake into proteoliposomes was monitored by the time-dependent
quenching of the fluorophore calcein trapped inside the vesicles (Figure 2—figure supplement 1A)
(Ehrnstorfer et al., 2017). In the absence of inhibitors, Mn2+ transport by EcoDMT saturates at low
micromolar concentrations (KM = 4.3 mM) (Figure 2—figure supplement 1C, Table 1). The addition
of either benzyl bis-isothiourea compound decreases the kinetics of uptake in a dose-dependent
manner thus suggesting that all tested compounds, when applied at micromolar concentrations to
the outside of proteoliposomes, inhibit the transport activity of EcoDMT by binding to a saturable
site of the protein (Figure 2A, Figure 2—figure supplement 1D,E). Since higher concentrations of
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TMBIT and oBr-BIT (i.e. >50 mM) did interfere with the assay, we restricted our quantitative charac-
terization to Br-BIT, where we do not observe any interference at concentrations up to 200 mM. At
high micromolar concentrations of Br-BIT, the decrease of transport activity approaches a maximum
and even at 200 mM Br-BIT we could not detect complete inhibition. The saturation of the inhibition
at high concentration results from the full occupancy of accessible binding sites, whereas the residual
transport likely originates from transporters with inside-out orientation which do not expose the pre-
sumed inhibitor binding site to the external solution. The basal activity at high inhibitor
Table 1. Transport kinetics and inhibition.
Protein Inhibitor KM (mM) vmax* Ki (mM) a
Michaelis-Menten Equation 2
hDMT1 - 3.1 ± 0.6 4.6 ± 0.3 0.57 ± 0.17 >100
1 mM Br-DBFIT 9.2 ± 1.2 4.2 ± 0.2
2.5 mM Br-DBFIT 14.7 ± 2.8 4.3 ± 0.4
5 mM Br-DBFIT 14.4 ± 3.0 3.4 ± 0.4
hDMT1 - 2.6 ± 0.5 2.6 ± 0.1 0.35 ± 0.07 17.4
0.25 mM TMBIT 4.0 ± 0.4 2.3 ± 0.1
0.5 mM TMBIT 6.1 ± 0.8 2.4 ± 0.1
1.25 mM TMBIT 8.0 ± 1.0 2.1 ± 0.1
hDMT1 - 2.9 ± 0.4 3.1 ± 0.1 0.08 ± 0.01 >100
0.25 mM TEBIT 13.1 ± 3.3 3.0 ± 0.4
0.5 mM TEBIT 18.3 ± 5.3 2.9 ± 0.5
1.25 mM TEBIT 26.8 ± 8.6 2.5 ± 0.5
hDMT1 - 2.6 ± 0.5 2.6 ± 0.1 3.6 ± 0.7 13.5
5 mM Br-BIT 6.7 ± 0.7 2.4 ± 0.1
10 mM Br-BIT 7.4 ± 1.2 2.2 ± 0.1
25 mM Br-BIT 12.4 ± 3.7 1.6 ± 0.2
hDMT1 S476V - 2.3 ± 0.5 - - -
hDMT1 N520L - 2.4 ± 0.5 - - -
hDMT1 F523A - 2.7 ± 0.6 - - -
EcoDMT - 4.3 ± 0.5 21.9 ± 0.5 14.2 ± 2.6 >100
10 mM Br-BIT 13.7 ± 1.2 21.7 ± 0.4
50 mM Br-BIT 21.7 ± 3.6 21.4 ± 1.0
100 mM Br-BIT 31.5 ± 6.9 20.4 ± 1.3
EcoDMT N456A - 12.5 ± 1.7 19.1 ± 0.6 29.3 ± 7.1 8.5
10 mM Br-BIT 17.8 ± 4.0 18.3 ± 1.1
50 mM Br-BIT 28.8 ± 5.4 14.9 ± 0.8
100 mM Br-BIT 33.9 ± 6.9 13.8 ± 0.8
EcoDMT N456L - 7.5 ± 0.7 17.3 ± 0.4 28.8 ± 5.3 29.2
10 mM Br-BIT 13.1 ± 1.7 16.2 ± 0.5
50 mM Br-BIT 19.0 ± 2.4 13.8 ± 0.5
100 mM Br-BIT 27.0 ± 3.9 15.1 ± 0.6
EcoDMT N456A S459A Q463A 7.2 ± 0.9 21.9 ± 0.5 23.8 ± 3.2 >100
10 mM Br-BIT 15.7 ± 1.7 21.7 ± 0.4
50 mM Br-BIT 32.3 ± 4.5 21.4 ± 1.0
100 mM Br-BIT 47.9 ± 5.6 20.4 ± 1.3
*nmax values for hDMT1 measurements are given in pmol min
 1 well 1 and nmax values for EcoDMT measurements in DF Dt 1.
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concentration thus further demonstrates the sidedness of the inhibition and the membrane-imper-
meability of the compound. As for the inhibition of hDMT1, the KM values of transport increased at
higher inhibitor concentrations, whereas vmax did not show pronounced changes (Figure 2B,
Table 1). The Ki value of 14.2 mM, representing the equilibrium dissociation constant to the sub-
strate-free EcoDMT, is in the same range as the Ki value of 3.6 mM obtained for hDMT1, reflecting
the strong structural relationship between both proteins. Together, our results suggest that Br-BIT
inhibits EcoDMT and hDMT1 by a common competitive mechanism.
Structural characterization of the inhibition of EcoDMT by Br-BIT
To investigate the structural basis for the inhibition of divalent metal ion transporters of the SLC11
family by benzyl bis-isothiourea-based compounds, we have characterized the interaction between
the brominated analogs and EcoDMT by X-ray crystallography. In our experiments we exploited the
anomalous scattering properties of the inhibitors to facilitate their localization in the complex. For
that purpose, we have soaked crystals of EcoDMT with Br-BIT and oBr-BIT and collected multiple
datasets at a wavelength corresponding to the anomalous absorption edge of bromine (Table 2,
Table 3). Whereas we were unable to detect bromine in the anomalous maps of oBr-BIT containing
crystals, the majority of datasets collected from crystals soaked with Br-BIT displayed a single strong
peak in the anomalous difference density at equivalent positions, which aided the localization of the
bound inhibitor (Figure 3A,B, Figure 3—figure supplement 1A, Table 3). A detailed view of the
complex defined in the 2Fo-Fc density at 3.8 A˚ is displayed in Figure 3A. In this structure, EcoDMT
adopts the same substrate-free outward-facing conformation that has previously been observed in
datasets of the protein in absence of the inhibitor (Figure 3C,D) (Ehrnstorfer et al., 2017). In this
conformation, a funnel-shaped aqueous pocket of the protein leads from the extracellular solution
to the substrate binding site. The inhibitor is bound at the base of this pocket as defined by the
anomalous difference density that constrains the position of the covalently bound Br-atom and by
residual density in the 2Fo-Fc omit map that was calculated with phases from a model not containing
the inhibitor (Figure 3B). The fact that the Br-Atom of Br-BIT is located in the narrow apex of the
pocket, whereas it would be placed in the wider part of the cavity in oBr-BIT might explain why we
were unable to detect the binding position in the anomalous difference density of the latter com-
pound. The omit map of the EcoDMT Br-BIT complex displays density for the aromatic ring and for
Figure 2. Inhibition of EcoDMT by Br-BIT. (A) EcoDMT mediated Mn2+ transport into proteoliposomes in presence of Br-BIT assayed by the quenching
of the fluorophore calcein trapped inside the vesicle. Br-BIT was added at different concentration (5–200 mM) to the outside of the liposomes. The
transport is started by the addition of the potassium ionophore Valinomycin (Val) and 5 mM MnCl2. To equilibrate the Mn
2+ ions, the ionophore
Calcimycin (Cal) was added at the end of the run. Schematic figure (left) depicts the sidedness of inhibition which is responsible for the remaining
activity at large inhibitor concentrations. (B) Transport kinetics of EcoDMT at the indicated Br-BIT concentrations. The solid lines are fits to the
Michaelis-Menten equation assuming similar kinetic properties of transport for both orientations of the transporter. The observed kinetic parameters
thus describe apparent values obtained from an average of transport properties in inside-out and outside-out orientations. Values show averages of six
technical replicates obtained from three independent proteoliposome preparations, errors are s.e.m.
The online version of this article includes the following figure supplement(s) for figure 2:
Figure supplement 1. Characterization of EcoDMT inhibition.
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the isothiourea group located close to the metal ion binding site (termed proximal isothiourea
group), whereas the other group (the distal isothiourea group) is not defined in the electron density
reflecting its increased conformational flexibility (Figure 3B). In general, the shape of the binding
pocket is complementary to the structure of the inhibitor but it is sufficiently wide in the long direc-
tion of the molecule to accommodate substitutions at the aromatic ring as found in the molecules
TMBIT, TEBIT and in the larger dibenzofuran ring of Br-DBFIT (Figure 3E). The aromatic group is
stacked between a-helices 6 and 10 contacted by the side chains of residues Ala 231, Leu 410, Ala
409 and Leu 414. The close-by Asn 456 located on a11 might interact with the covalently attached
Br atom of Br-BIT (Figure 3F, Figure 3—figure supplement 1B). The proximal isothiourea group is
located in a narrow pocket in interaction distance to the conserved Asp 51 and Asn 54 in the
unwound part of a 1 and to Gln 407 on a 10, which were shown to contribute to the coordination
of transported metal ions (Figure 3E,F, Figure 3—figure supplement 1B) (Bozzi et al., 2019;
Ehrnstorfer et al., 2014; Ehrnstorfer et al., 2017; Pujol-Gime´nez et al., 2017). The distal iso-
thiourea group is located in the wider entrance of the cavity and might thus adopt different confor-
mations, which is consistent with its undefined position in the electron density (Figure 3B). In one
conformation, this group approaches residues Ser 459 and Gln 463, both located on a11. Besides
the direct ionic interactions of the proximal isothiourea group with Asp 51, the positive charge of
both groups would be additionally stabilized by the negative electrostatics of the pocket that is con-
ferred by an excess of acidic residues (Figure 3—figure supplement 1C). The observed binding
Table 2. X-ray data collection and refinement statistics.
EcoDMT-Br-BIT complex
Data collection
Space group C2
Cell dimensions
a, b, c (A˚) 150.0, 81.7, 95.6
a, b, g (˚) 90, 107.4, 90
Wavelength (A˚) 0.92
Resolution (A˚) 50–3.8 (3.9–3.8)*
Rmerge (%) 9.8 (154.6)
CC½ (%) 100.0 (81.7)
I /sI 15.6 (2.1)
Completeness (%) 99.3 (99.3)
Redundancy 14.3 (13.9)
Refinement
Resolution (A˚) 12–3.8
No. Reflections 10576
Rwork/Rfree (%) 21.6/25.8
No. atoms
Protein 3780
Ligand/ion 17
Water -
B factors
Protein 171.3
Ligand/ion 237.1
r.m.s. deviations
Bond lengths (A˚) 0.005
Bond angles (˚) 0.65
*Values in parentheses are for highest-resolution shell.
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position and the assumed interaction of the inhibitor with the metal ion binding site is also compati-
ble with the observed competitive nature of the inhibition.
The high sequence similarity between bacterial and human orthologs (i.e. 52% similar and 29%
identical residues between EcoDMT and hDMT1) facilitates the construction of a homology model of
human DMT1 (Figure 3—figure supplement 2A,B), which permits a glimpse of potential interac-
tions of the inhibitor with the human transporter. As this model does not contain any insertions or
deletions in the binding region, we expect a similar-shaped outward-facing cavity binding the inhibi-
tor in hDMT1 as observed for EcoDMT (Figure 3G, Figure 3—figure supplement 2B). The conser-
vation is particularly high for a-helices 1 and 6 constituting the metal ion coordination site, but
differences are observed for pocket-lining residues located on a-helices 10 and 11: While the corre-
sponding residues Leu 414 in EcoDMT and Leu 479 in hDMT1 (both located on a10) seal the bottom
of the binding cavity in both proteins, the hydrophobic character of Leu 410 and Ala 409 in EcoDMT,
which contact one face of the aromatic ring is altered by the polar sidechains of Gln 475 and Ser 476
in hDMT1 (Figure 3F,H, Figure 3—figure supplement 2A). Close to the ion coordination site, Gln
407 of EcoDMT, which potentially interacts with the proximal isothiourea group, is substituted by an
Asn 472 in hDMT1 (Figure 3F,H). Among the a-helices constituting the inhibitor binding site, a 11
is least conserved between hDMT1 and EcoDMT (Figure 3—figure supplement 2A). Whereas Asn
456 of EcoDMT, which contacts the Br atom of Br-BIT is conserved in hDMT1 (Asn 520), Ser 459 and
Gln 463 of the bacterial transporter are replaced by bulky aromatic residues (Phe 523 and Tyr 527),
which could decrease the volume of the binding pocket in hDMT1 and thus potentially constrain the
conformation of the distal isothiourea group (Figure 3F,G,H). Nevertheless, since both residues are
located in the wider part of the binding pocket, it is justified to assume a similar general binding
mode of the inhibitor in bacterial and human orthologues. As for EcoDMT, we expect that the
strongly negative electrostatic potential within the binding pocket of hDMT1 favors the binding of
the positively charged inhibitor (Figure 3—figure supplement 2C). Taken together, our structural
data thus provide a detailed view of the molecular basis of the interaction of benzyl bis-isothiourea-
based inhibitors with divalent metal ion transporters of the SLC11/NRAMP family.
Functional characterization of inhibitor binding-site mutants of EcoDMT
To further characterize the binding of Br-BIT to EcoDMT, we have studied the effect of mutations of
putative contact residues identified in the structure on inhibition (Figure 4A). Although the
described results emphasize the importance of interactions of the isothiourea group with the metal-
Table 3. X-Ray data collection statistics of additional datasets.
EcoDMT-Br-BIT complexes 1 2 3 4 5
Data collection
Space group C2 C2 C2 C2 C2
Cell dimensions (A˚), (˚)
a b c 147.9
81.2
95.3
149.7
81.7
95.5
148.7
81.1
94.8
150.1
81.6
95.5
148.9
81.3
95.4
a
b
g
90
107.3
90
90
107.3
90
90
107.1
90
90
107.3
90
90
107.3
90
Wavelength (A˚) 0.92 0.92 0.92 0.92 0.92
Resolution (A˚) 50–3.8
(3.9–3.8)*
50–4.0
(4.1–4.0)*
50–4.3
(4.4–4.2)*
50–4.1
(4.2–4.1)*
50–4.2
(4.3–4.2)*
Rmerge (%) 6.7 (182.1) 7.8 (142.0) 7.2 (152.6) 8.3 (112.5) 11.8 (198.9)
CC½ (%) 100.0 (80.4) 100.0 (81.0) 100.0 (71.6) 100.0 (53.9) 100.0 (77.1)
I /sI 15.6 (1.5) 19.3 (1.6) 14.8 (1.4) 13.7 (1.6) 14.5 (1.5)
Completeness (%) 99.2 (99.7) 99.0 (99.5) 97.4 (74.0) 94.8 (40.5) 99.8 (100.0)
Redundancy 14.6 (14.6) 21.0 (11.7) 14.2 (11.8) 8.7 (5.1) 14.0 (14.4)
*Values in parentheses are for highest-resolution shell.
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Figure 3. Structure of inhibitor complexes. (A-B) Close-up views of the crystal structure of EcoDMT in complex
with Br-BIT determined at 3.8 A˚ resolution viewed from within the membrane. The refined 2Fo-Fc electron density
is shown as blue mesh. The position of Br-BIT is defined by the anomalous difference density of the Br-atom
(shown as magenta mesh, contoured at 7s) and by residual density in the 2Fo-Fc omit map (dark yellow mesh).
Figure 3 continued on next page
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coordination site, these cannot be probed with the applied transport assays as mutations of coordi-
nating resides interfere with ion uptake. We have thus employed isothermal titration calorimetry
(ITC) to directly measure the effect of a metal-binding site mutant in EcoDMT on inhibitor binding.
Figure 3 continued
C-D, Ribbon representations of the EcoDMT structure viewed from within the membrane (C) and from the
extracellular side (D). The Mn2+ binding site is indicated with a red asterisk. The molecular surfaces are
represented as gray meshes. The C-terminal sub-domain (a-helices 6–12) is shown in dark blue, a-helices 11 and
12 in magenta. (E) Position of Br-BIT in the binding pocket (gray mesh) of EcoDMT. (F) Detailed view of the
residues in contact distance to Br-BIT. (G) Position of Br-BIT in the binding pocket (gray mesh) of a homology
model of human DMT1. (H) Potential interactions of Br-BIT with the homology model of human DMT1. A-H, The
proximal (p) isothiourea group is close to the metal ion coordinating residues (marked with a black asterisk) and
the distal (d) isothiourea group is in proximity to a-helix 11.
The online version of this article includes the following figure supplement(s) for figure 3:
Figure supplement 1. Inhibitor binding to EcoDMT.
Figure supplement 2. Homology model of hDMT1.
Figure 4. Characterization of inhibitor interactions in EcoDMT mutants. (A) Close-up view of mutated residues
surrounding Br-BIT in EcoDMT. B-C, Binding isotherms obtained from isothermal titrations of Br-BIT to EcoDMT
WT (B) and the metal ion binding site mutant D51A (C). For WT, the data was fitted to a model assuming a single
set of binding sites with the binding isotherm shown as solid line. Error represent fitting errors. (D) Equilibrium
dissociation constants (Ki) of Br-BIT binding to WT and mutants of EcoDMT determined using the proteoliposome
transport assay and by fitting the data to the mixed enzyme inhibition model (Equation 2).
The online version of this article includes the following figure supplement(s) for figure 4:
Figure supplement 1. Isothermal titration calorimetry.
Figure supplement 2. Transport inhibition of EcoDMT mutants.
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In ITC experiments, we find two signals in the thermograms in response to the titration of the inhibi-
tor to the WT protein. A weak endothermic contribution, which saturates at low mM concentrations
(KD = 34.5 ± 5.0 mM) can be attributed to the loading of the inhibitor binding site and an exothermic
signal saturating with an affinity in the mM range to a potential non-specific interaction with the pro-
tein (Figure 4B, Figure 4—figure supplement 1A,B). To characterize the observed interaction
between the positively charged isothiourea group and the negatively charged Asp 51 of the metal-
binding site, we have expressed and purified the mutant D51A and measured inhibitor binding.
Whereas the low-affinity signal in the thermograms appears unaltered, the high affinity component
is absent, as expected if the mutant has removed an important interaction which interferes with
inhibitor binding (Figure 4C, Figure 4—figure supplement 1A,B). Thus, despite the weak signal
originating from the low enthalpic contribution to binding, our titration calorimetry experiments indi-
cate a direct interaction of the isothiourea group with the metal binding site as expected for a com-
petitive inhibitor.
To probe the role of other residues of EcoDMT in the vicinity of the bound inhibitor, we have
characterized the effect of alterations of three hydrophilic residues on a-helix 11 on the inhibition of
Mn2+ transport. Based on our structures, we suspected Gln 463 and Ser 459 to interact with the dis-
tal isothiourea group and Asn 456 with the bromine atom on the aromatic ring of Br-BIT
(Figure 4A). The three constructs, the single mutants N456A and N456L and the triple mutant
N456A/S459A/Q463A transport Mn2+ with similar kinetics as WT (Figure 4—figure supplement
2A–C, Table 1). As for WT, Mn2+ transport in all three mutants is inhibited upon addition of Br-BIT,
although with slightly decreased potency (Ki: WT, 14.2 mM; N456A, 29.3 mM; N456L, 28.8 mM;
N456A/S459A/Q463A, 23.8 mM) (Figure 4D, Figure 4—figure supplement 2D–F, Table 1). In light
of the small difference in Ki compared to WT, our data excludes a large energetic contribution of
residues on a11 to inhibitor binding, consistent with the assumed mobility of the distal isothiourea
group that is manifested in the lack of electron density of the group in the structures of EcoDMT Br-
BIT complexes.
Functional characterization of inhibitor binding-site mutants of hDMT1
To characterize the role of residues in the predicted inhibitor binding pocket of human DMT1, we
have generated several point mutants and investigated the effect of these mutations on the interac-
tion with different inhibitors. Due to the strong negative impact of alterations of the metal ion coor-
dination site on transport, mutagenesis was restricted to residues lining the remainder of the
binding pocket. The investigated positions encompassed residues on a 6 (Ala 291), a 10 (Gln 475,
Ser 476 and Leu 479), and a 11 (Asn 520, Phe 523 and Tyr 527) (Figures 3H and 5A). In our experi-
ments we wanted to target interactions of protein residues with the aromatic ring in the narrow part
of the binding pocket by either shortening the side-chains in the mutants A291G and Q475A, or by
increasing their size in the mutants A291V, Q475F, S476V and L479F. In the orthogonal direction,
the binding pocket is wider and would on one side be delimited by resides located on a 11
(Figures 3G and 5A). Based on our model, we suspected the aromatic side chains of Phe 523 and
Tyr 527 to be located in proximity to the distal isothiourea groups of TMBIT, TEBIT and Br-BIT or to
the second phenyl-ring in the case of the dibenzofuran-based compound Br-DBFIT and Asn 520 in
interaction distance with the aromatic ring harboring the proximal isothiourea group in all com-
pounds (Figures 3H and 5D). To probe these potential interactions, we have truncated the aromatic
side chains in the mutants F523A and Y527A and generated a nearly isosteric hydrophobic substitu-
tion in the mutant N520L and subsequently studied the 55Fe2+ uptake properties of HEK293 cells
transiently transfected with DNA coding for the respective constructs. Transport is similar to WT in
case of the mutants S476V, F523A and Y527A, reduced in the mutants Q475A and N520L and unde-
tectable in the mutants A291G, A291V, Q475F and L479F (Figure 5B, Figure 5—figure supplement
1A). Mutations that render hDMT1 inactive, most likely interfere with structural rearrangements dur-
ing ion transport, as judged by the tight packing of the respective region in the inward-facing struc-
tures of SLC11 transporters (Bozzi et al., 2016b; Bozzi et al., 2019; Ehrnstorfer et al., 2014).
Inhibition experiments on hDMT1 were carried out with Br-BIT used for crystallization, the more
potent inhibitors TMBIT and TEBIT and the dibenzofuran-based compound Br-DBFIT to explore the
influence of the aromatic scaffold and the geometric relationship between the two isothiourea
groups on interactions. Similar to WT, the addition of either compound at equivalent concentrations
decreases uptake in the mutants Y527A and Q475A both located towards the extracellular entrance
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to the binding pocket (Figures 3H and 5A,C and Figure 5—figure supplement 1B–D) thus suggest-
ing that interactions with these residues do not strongly contribute to inhibitor binding. Conversely,
the compounds had much smaller effects on the transport activity of cells expressing the mutants
S476V, N520L and F523A located deeper in the binding pocket (Figures 3H and 5C,D, Figure 5—
figure supplement 1B–C) thus suggesting that in these cases, the mutations affected inhibitor inter-
actions. To further characterize the inhibitory properties of the investigated compounds, we have
measured uptake at different inhibitor concentrations and found a strong reduction in potency in
most cases (Figure 5E, Table 4). Whereas the effect is uniform in the mutant S476V for all investi-
gated compounds, the mutants N520L, and F523A showed a decreased potency of inhibition for the
related molecules Br-BIT, TMBIT and TEBIT but only a slight reduction for Br-DBFIT (Figure 5E, Fig-
ure 5—figure supplement 1E, Table 4) indicating that residues on a 11 might form distinct interac-
tions with different inhibitor classes. This is consistent with the wide dimensions of the pocket in that
direction that allows for a geometry-dependent placement of the aromatic ring and the attached iso-
thiourea moiety on the distal side (Figure 5D). Taken together our results suggest an involvement of
residues on a 10 and a 11 on inhibitor binding to hDMT1 although with variable specificity, consis-
tent with the proposed general binding mode of the inhibitors, which constrain the binding of the
first aromatic ring to position the proximal isothiourea group in interaction distance with the
Figure 5. Characterization of inhibitor interactions in hDMT1 mutants. A, D Close-up view of mutated residues surrounding Br-BIT (A, D) and Br-DBFIT
(D) in a homology model of hDMT1. (B) Transport activity of HEK293 cells transiently transfected with a vector not containing an insert (EV) or with WT
and human DMT1 mutants determined using a cellular iron uptake assay. Data show mean of 15–39 replicates, errors are s.d. (C) Inhibition of cellular
iron uptake by 10 mM TEBIT of HEK293 cells transiently transfected with WT and mutants of human DMT1 at 1 mM Fe2+. Data show mean of 6–9
replicates, errors are s.d. (E) Characterization of inhibitory properties of Br-BIT, TMBIT, TEBIT and Br-DBFIT in HEK293 cells transiently transfected with
the respective hDMT1 mutants. The ratio of IC50 WT / IC50 mutant is displayed. Low values, reflect a strong effect of the mutation on inhibition. As Br-
BIT did not inhibit transport of the mutant N520L at the tested concentrations, IC50 ratios are not displayed (-).
The online version of this article includes the following figure supplement(s) for figure 5:
Figure supplement 1. Transport inhibition of hDMT1 mutants.
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metal ion coordination site. Since equivalent mutations of a11 in EcoDMT had little impact on inhibi-
tion of Br-BIT, our results also point towards species-dependent energetic differences in inhibitor
interactions on the distal side of the inhibitor binding pocket, which are reflected in the poor conser-
vation of residues in a11 and the wide geometry of the pocket in the prokaryotic transporter.
Despite the described species-dependent differences, our data is generally consistent with the
notion that the characterized compounds inhibit both pro- and eukaryotic transporters by binding to
equivalent regions.
Discussion
By combining chemical synthesis with X-ray crystallography and in vitro binding and transport assays
on human DMT1 and its prokaryotic homologue EcoDMT, our study has revealed detailed insight
into the inhibition of SLC11 transporters by aromatic bis-isothiourea-based compounds. These com-
pounds inhibit pro- and eukaryotic family members by a predominant competitive mechanism by
binding to an outward-facing aqueous cavity leading to the transition metal ion coordination site
(Figures 1, 2, 3 and 6) which prevents substrate loading and the transition to an inward-open con-
formation of the transporter. We have shown that these compounds do not interact with the reactive
transported substrate, which has hampered the identification of specific inhibitors in high-through-
put screens (Figure 1—figure supplement 1B). We have also shown that these compounds are posi-
tively charged and thus poorly membrane permeable and most likely attracted and stabilized by the
strong negative electrostatic potential in the outward-facing aqueous cavity (Figure 1—figure sup-
plement 1A, Figure 3—figure supplements 1C and 2C). Our structural studies have identified the
binding mode of the inhibitors at the base of the funnel-shaped cavity, with the aromatic group
snugly fitting into the pocket, thereby positioning the isothiourea group into ideal interaction dis-
tance with the aspartate of the transition metal binding site (Figures 3A,B and 6B). Although the
characterization of the interaction to the metal ion binding site is experimentally challenging, since
mutations at this site interfere with transport (Bozzi et al., 2019; Ehrnstorfer et al., 2014;
Ehrnstorfer et al., 2017; Pujol-Gime´nez et al., 2017), it is supported by several observations: First,
the interaction of the isothiourea group with the metal ion binding site is displayed in the electron
density of the complex (Figure 3A,B). Second, the low micromolecular binding affinity of the inhibi-
tor to the prokaryotic transporter EcoDMT observed in titration calorimetry experiments vanishes in
a mutant truncating the binding site aspartate (Figure 4B,C, Figure 4—figure supplement 1A,B)).
Third, the interaction underlies the observed competitive mechanism that is shared by all investi-
gated isothiourea-based compounds containing different aromatic substituents (Figure 1, Figure 1—
figure supplement 3), and fourth it underlines the strong requirement for the isothiourea group for
potent inhibition. Latter is illustrated by the inhibition of human DMT1 by compounds where either
one or both isothiourea groups are modified, leading to moderately reduced potency in the first,
and a strongly reduced binding affinity in the second compound (Figure 1B, Figure 1—figure sup-
plement 2E,F,G). In our proposed inhibition mechanism, the role of the aromatic group in each
compound is to position the inhibitor at the base of the predominantly hydrophobic pocket in prox-
imity to the binding site (Figure 6B). This is supported by the fact that a mutation in hDMT1 that
likely narrows the pocket in this direction (S476V) leads to a reduced potency of inhibition
(Figure 5C,E, Figure 5—figure supplement 1B–E, Table 4). In the orthogonal direction, the funnel-
Table 4. IC50 values (mM) of WT and mutant proteins.
TEBIT TMBIT Br-BIT Br-DBFIT
WT 0.48 ± 0.09 1.28 ± 0.54 4.2 ± 1.5 1.43 ± 0.34
S476V 32.1 ± 6.3 36.1 ± 8.0 47.6 ± 6.8 11.3 ± 0.3
N520L 13.7 ± 3.9 21.7 ± 6.9 - 2.0 ± 0.4
F523A 17.8 ± 7.0 82.9 ± 5.3 17.3 ± 0.5 2.9 ± 0.9
Measurements were performed using 1 mM Fe2+ with transiently transfected HEK293 cells expressing the indicated
hDMT1 constructs. The values shown for WT deviate from the values shown in Figure 1—figure supplement 2, due
to small differences in the experimental setup (i.e. the use of a stable cell line vs. transiently transfected cells).
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shaped pocket is sufficiently wide to accommodate larger groups, which might undergo successively
stronger interactions, which is illustrated by the increased potency of two compounds containing
additional alkyl modification at the aromatic ring (as it is the case for TMBIT and TEBIT)
(Figures 1B and 6B; Figure 1—figure supplement 2B,C). This general mode of interaction might
also explain the inhibition of isothiourea-based compounds with larger ring systems as it is the case
for the dibenzofuran Br-DBFIT (Figures 1B and 6B; Figure 1—figure supplement 2A) and related
compounds characterized in a previous study (Zhang et al., 2012). Whereas one isothiourea group
strongly interacts with the metal ion binding site in both pro- and eukaryotic transporters, the oppo-
site groups reside in the wider exit of the cavity in a region that is poorly conserved between differ-
ent SLC11 homologues (Figure 3E,G, Figure 3—figure supplement 2A). In EcoDMT it most likely
undergoes no specific interactions with the protein and instead exhibits large conformational flexibil-
ity as supported by the absence of electron density for this group in the X-ray structure of the inhibi-
tor complex and by the mostly unaltered potency in mutants of potentially interacting residues
(Figures 3A,B, 4 and 6B). In contrast, mutations of equivalent positions in human DMT1 show a
more pronounced effect thus pointing towards stronger inhibitor interactions distal to the metal
binding site compared to EcoDMT (Figures 5 and 6B). This is generally supported by the reduced
potency of an asymmetric compound binding to human DMT1 where only one of the isothiourea
groups was modified (Figure 1—figure supplement 2F). In this case the effect of the modification
could be explained by a moderate decrease in the interaction at the distal side where interactions
with the protein might be less specific and by the reduced entropy of binding of the asymmetric
compound with the metal ion binding site, which demands interaction with the isothiourea group
(Figure 6). A strategy to increase the potency and selectivity of compounds towards human DMT1
Figure 6. Inhibition mechanism. (A) Scheme of the inhibitor binding to the outward-facing cavity of an SLC11 transporter thereby preventing substrate
binding and conformational changes. (B) Interactions of the transported ion and different inhibitors with the outward-facing cavity of EcoDMT and
hDMT1. The shape of the cavity is indicated, the sidechain of the conserved aspartate of the metal ion binding site and the chemical structures of
different inhibitors are shown.
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could thus rely on the optimization of interactions at the distal side of the binding pocket by a sys-
tematic variation of aromatic scaffolds and attached polar groups.
In summary we have provided the first detailed mechanistic insight into the pharmacology of tran-
sition metal transporters of the SLC11 family. Our results are relevant for potential therapeutic strat-
egies inhibiting human DMT1, which could be beneficial in cases where excessive uptake of iron in
the intestine leads to iron overload disorders as observed in hereditary or secondary hemochromato-
sis, and our study provides a framework that might aid the improvement of these compounds to
optimize both their potency and specificity.
Materials and methods
Key resources table
Reagent type
(species) or
resource Designation
Source or
reference Identifier Additional information
Chemical
compound,
drug
Opti-MEM Thermo fisher
Scientific
Cat#11058021
Chemical
compound,
drug
Lipofectamine
2000 Transfection
Reagent
Thermo fisher
Scientific
Cat#11668027
Chemical
compound,
drug
Dulbecco’s Modified
Eagle’s Medium -
high glucose
MERCK Cat#D6429
Chemical
compound,
drug
Fetal Bovine
Serum (FBS)
MERCK Cat#F7524
Chemical
compound,
drug
MEM Non-essential
Amino Acid Solution
(100x)
MERCK Cat#M7145
Chemical
compound,
drug
Poly-D-lysine hydrobromide MERCK Cat#P6407
Chemical
compound,
drug
Penicillin-Streptomycin MERCK Cat#P4333
Chemical
compound,
drug
HEPES solution MERCK Cat#H0887
Chemical
compound,
drug
Sodium pyruvate
solution
MERCK Cat# S8636
Chemical
compound,
drug
MicroScint-20 PerkinElmer Cat# 6013621
Chemical
compound,
drug
Iron-55 Radionuclide
as Ferric
chloride/s.A.>3 Ci/g,
Ferric chloride in
0.5MHCl
ANAWA
Biomedical Services
and Products
Cat# ARX-0109–2
Chemical
compound,
drug
Terrific Broth (TB) medium Sigma Cat#T9179
Chemical
compound,
drug
Ampicillin AppliChem Cat#A0839
Chemical
compound,
drug
L-(+)-Arabinose Sigma-Aldrich Cat#A3256
Continued on next page
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Continued
Reagent type
(species) or
resource Designation
Source or
reference Identifier Additional information
Chemical
compound,
drug
Lysozyme AppliChem Cat#A3711
Chemical
compound,
drug
DNase I AppliChem Cat#A3778
Chemical
compound,
drug
n-decyl-b-D-
maltoside (DM)
Anatrace Cat#D322
Chemical
compound,
drug
n-dodecyl-b-D-maltoside (DDM) Anatrace Cat#D310
Chemical
compound,
drug
1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphoethanolamine
(POPE)
Avanti Polar
Lipids, Inc
Cat#850757
Chemical
compound,
drug
1-palmitoyl-2-oleoyl-
sn-glycero-3-phospho-
(1’-rac-glycerol)
(POPG)
Avanti Polar
Lipids, Inc
Cat#840457
Chemical
compound,
drug
Diethyl ether Millipore Sigma Cat#296082
Chemical
compound,
drug
Triton X-100 Millipore Sigma Cat#T9284
Chemical
compound,
drug
Calcein Thermo Fisher
Scientific
Cat#C481
Chemical
compound,
drug
Valinomycin Thermo Fisher
Scientific
Cat#V1644
Chemical
compound,
drug
A-23187 Free
Acid (Calcimycin)
Thermo Fisher
Scientific
Cat#A1493
Peptide,
recombinant
protein
HRV 3C protease Expressed and
purified (Expression vector
pET-3C) Raimund
Dutzler laboratory
N/A
Commercial
assay or kit
Corning96 Well
Black Polystyrene
Microplate
MERCK Cat# CLS3603
Commercial
assay or kit
PfuUltra High-fidelity
DNA Polymerase
Agilent Technologies Cat# 600380
Commercial
assay or kit
Nickel NTA
Agarose Resin
ABT Agarose
Bead Technologies
6BCL-NTANi-X
Commercial
assay or kit
Superdex 200
10/300 GL
GE Healthcare Cat#17517501
Commercial
assay or kit
24-well Cryschem
M crystallization
plate
Hampton
Research
Cat#HR1-002
Commercial
assay or kit
Bio-Beads SM-2 Bio-Rad Cat#1523920
Commercial
assay or kit
Avestin LiposoFast
Liposome Factory
Basic
Millipore Sigma Cat#Z373400
Continued on next page
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Continued
Reagent type
(species) or
resource Designation
Source or
reference Identifier Additional information
Commercial
assay or kit
400 nm polycarbonate
filters for LiposoFast
Millipore Sigma Cat#Z373435
Commercial
assay or kit
96-well black-
walled microplate
Thermo Fisher Scientific Cat#M33089
Commercial
assay or kit
Amicon 50 kDa
MWCO centrifugal filter
EMD Millipore Cat#UFC805024
Commercial
assay or kit
0.22 mm Ultrafree-
MC Centrifugal Filter
EMD Millipore Cat#UFC30GV
Strain,
strain background
Escherichia
coli MC1061
Thermo Fisher
Scientific
Cat#C66303
Strain, strain
background
Eremococcus coleocola strain https://www.
dsmz.de/collection
DSM No. 15696
Cell line
(human)
HEK-293 ATCC CRL-1573
Cell line
(human)
HEK-293T ATCC CRL-3216
Recombinant
DNA
Human SLC11A2
isoform 1A-IRE
(+) ORF inserted
in pBluescript
SK - vector
Hentze laboratory-
EMBL, Heildelberg,
Germnay
N/A
Recombinant
DNA
pIRES2
DsRed-Express2
Vector
Takara Clontech Cat# 632540
Recombinant
DNA
Expression
vector pBXC3GH
Addgene Cat#47070
Recombinant
DNA
Expression
vector pBXC3H
Addgene Cat#47068
Recombinant
DNA
Expression
vector pET-3C
Dr. Arie Geerlof,
EMBL Munich
N/A
Software,
algorithm
XDS Kabsch, 2010 http://xds.mpimf-heidelberg.mpg.de/
Software,
algorithm
CCP4 Collaborative Computational
Project, 1994
http://www.
ccp4.ac.uk/
Software,
algorithm
Coot 0.8.9 Emsley and
Cowtan, 2004
https://www2.mrc-lmb.cam.ac.uk/
personal/
pemsley/coot/
Software,
algorithm
PHENIX 1.17 Adams et al., 2002 http://phenix-online.org/
Software,
algorithm
MSMS Sanner et al., 1996 http://mgltools.
scripps.edu/
packages/MSMS/
Software,
algorithm
DINO 0.9.4 http://www.
dino3d.org
http://www.dino3d.org
Software,
algorithm
LIGPLOT Wallace et al., 1995 https://www.ebi.
ac.uk/thornton-
srv/software/LIGPLOT/
Software,
algorithm
CHARMM Brooks et al., 1983 https://www.
charmm.org/charmm/
Software,
algorithm
SWISS-MODEL Biasini et al., 2014 https://swissmodel.
expasy.org/
Software,
algorithm
Prism 8.3.0 GraphPad https://www.
graphpad.com/
Continued on next page
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Continued
Reagent type
(species) or
resource Designation
Source or
reference Identifier Additional information
Software,
algorithm
Microcal
Origin 5.0
Microcal Software, Inc. http://www.
microcal.com
Software,
algorithm
MicroCal
Concat ITC
Malvern
Panalytical
https://www.
malvernpanalytical.
com/en/
Chemical synthesis
The chemical synthesis of all compounds is described in Appendix 1.
Cell lines
Experiments using human cell lines were conducted with HEK293 cells either stably (ATCC-CRL-
1573) or transiently (ATCC-CRL3216) over-expressing DsRED-hDMT1 constructs. The cell line stably
over-expressing hDMT1 has been characterized previously (Montalbetti et al., 2014). Mycoplasma
contamination was negative for both cell lines as tested with the LooKOut Mycoplasm PCR Detec-
tion Kit (Sigma-MP0035). All cells were grown in DMEM media (Invitrogen) supplemented with 10%
FBS, 10 mM HEPES and 1 mM Na-pyruvate at 37˚C, 95% humidity and air containing 5% CO2. For
cells stably over-expressing hDMT1, the media was additionally supplemented with 500 mg ml–1
geneticin (Life Technologies).
Construct generation
The sequence coding for the hDMT1 isoform 1A-IRE (+) (UniProt identifier P49281-3) was cloned
into pIRES2 DsRed-Express2 bicistronic vector (Montalbetti et al., 2014). Single-point mutations
A291G, A291V, Q475A, Q475F, S476V, L479F, N520L, F523A and Y527A were introduced into the
hDMT1 encoding sequence as previously described (Pujol-Gime´nez et al., 2017). For EcoDMT, the
corresponding gene (UniProtKB identifier E4KPW4) was cloned using genomic DNA isolated from a
Eremococcus coleocola strain (DSM No. 15696) into the arabinose-inducible expression vectors
pBXC3GH and pBXC3H with fragment-exchange (FX) cloning (Geertsma and Dutzler, 2011). The
point mutations N456A, N456L, S459A and Q463A were introduced by site-directed mutagenesis
(Li et al., 2008).
Iron uptake and inhibition assays for hDMT1
For uptake experiments, HEK293 cells were grown in clear bottom, white-well, poly-D-lysine coated
96 well plates (Corning). Cells stably over-expressing hDMT1 were seeded 24 hr before the experi-
ment at a density of 50,000 cells/well and cells used for transient transfection were seeded at 30.000
cells/well for 48 hr prior to the experiment and transfected 24 hr before the experiment using Lipo-
fectamine 2000 (Life technologies) as described in the manufacturer’s protocol. Briefly, culture media
was removed from the wells and the cells were washed three times with uptake buffer (140 mM
NaCl, 2.5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 1.2 mM K2HPO4, 10 mM glucose, 5 mM HEPES, 5
mM MES, pH 7.4). After the wash, the cells were incubated for 15 min at room temperature (RT)
with uptake solution containing the indicated amount of non-radioactive ferrous iron (Fe2+), 100 mM
Ascorbic acid and 0.5 mCi/ml radiolabeled 55Fe2+ (American Radiolabeled) dissolved in uptake buffer
(pH 5.5). After incubation, uptake solution was removed from the wells, and the cells were washed
three times in ice-cold uptake buffer (pH 7.5). Before quantification, a scintillation cocktail (Mycro-
sinth 20, PerkinElmer) was added to each well, and the cells were incubated during 1 hr at RT under
constant agitation. Accumulated radioactivity was measured using a TopCount Microplate Scintilla-
tion Counter (PerkinElmer). Transport rates were quantified with:
influx rate¼
counts=well cpmð Þ substrate½  pMð Þ
total counts cpm=Lð Þ uptake time minð Þ
(1)
To assess their inhibitory effect, cells were incubated with the indicated compounds at the speci-
fied concentrations during 5 min at RT prior to the addition of the uptake solution. To determine the
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kinetic parameters for the Fe2+ transport mediated by hDMT1 WT and point mutants, the influx
rates at different iron concentrations were fitted to the Michaelis-Menten equation. For the determi-
nation of IC50 values, influx rates for each inhibitor concentration were plotted and data was fitted
to a 4-parameter sigmoidal curve. Plotted influx rates correspond to the mean of the indicated bio-
logical replicates, errors are s.d. Each experiment was performed in duplicates for transiently trans-
fected cells with data obtained from at least two independent transfections or triplicates for stably
overexpressed WT hDMT1.
Expression and purification of EcoDMT
EcoDMT WT and mutants were expressed in E. coli MC1061 as C-terminally-tagged fusion proteins
containing a 3C-protease cleavage site followed by a His10-tag. The tag was removed during purifi-
cation unless specified otherwise. E. coli cells were grown in Terrific Broth (TB) medium supple-
mented with 100 mg ml–1 ampicillin, either by fermentation or in flasks. Cells were grown at 37˚C and
the temperature was gradually decreased to 25˚C prior to induction. Protein expression was induced
by addition of 0.0045% (w/v) L-arabinose at an OD600 of ~2.5 for fermenter cultures and ~0.8 for cul-
tures in flasks. For overnight expression the temperature was decreased to 18˚C and cells were sub-
sequently harvested by centrifugation. All following protein purification steps were carried out at 4˚
C. The cells were lysed in buffer A (20 mM HEPES, pH 7.5, and 150 mM NaCl) supplemented with 1
mg ml–1 (w/v) lysozyme and 20 mg ml–1 DNaseI using HPL6 high-pressure cell disruptor (MAXIMA-
TOR). The lysate was subjected to a low-spin centrifugation (10,000 g for 20 min) and subsequently
the membrane vesicles were harvested by ultracentrifugation (200,000 g for 1 hr). Membrane pro-
teins were extracted by resuspending the vesicles in buffer A containing 10% (w/v) glycerol and 1–
2% (w/v) of the specified detergents and subsequently the extract was cleared by centrifugation.
The detergent n-decyl-b-D-maltopyranoside (DM, Anatrace) was used to purify proteins for reconsti-
tution or crystallization experiments and n-dodecyl-b-D-maltopyranoside (DDM, Anatrace) for iso-
thermal titration calorimetry (ITC). The extracted proteins were purified by immobilized metal affinity
chromatography (IMAC). The GFP- His10 tag was removed by addition of HRV-3C protease at a pro-
tein:protease molar ratio of 5:1 for 2 hr while dialyzing the sample against 20 mM HEPES, pH 7.5,
150 mM NaCl, 8.7% (w/v) glycerol, and 0.1% (w/v) DM or 0.04% (w/v) DDM. A second IMAC step
was used to separate the GFP-His10 tag and the protease from the cleaved protein. Subsequently,
the purified membrane proteins were subjected to size exclusion chromatography on a Superdex
S200 column (GE Healthcare) equilibrated in 10 to 20 mM HEPES, pH 7.5, 150 mM NaCl, and either
0.25% (w/v) DM or 0.04% (w/v) DDM. Peak fractions were used for reconstitution into liposomes,
ITC and crystallization experiments. Purified samples of WT and mutant proteins were analyzed by
SDS-PAGE and mass spectrometry.
X-ray structure determination
Crystals of EcoDMT were grown in 24-well plates in sitting drops at 4˚C by mixing 1 ml of protein (at
a concentration of 7–10 mg ml–1) with 1 ml of reservoir solution consisting of 50 mM Tris-HCl pH 8.0–
9.0 and 22–26% PEG 400 (v/v) and equilibrated against 500 ml of reservoir solution. Crystals grew
within two weeks. For preparation of inhibitor complexes, crystals were soaked for several minutes
with either Br-BIT or oBr-BIT. The two inhibitors were either added to the cryoprotection solutions at
a final concentration of 5 mM or directly added as powder to the drops containing the crystals. For
cryoprotection, the PEG 400 concentration was increased stepwise to 35% (v/v). All data sets were
collected on frozen crystals on the X06SA or the X06DA beamline at the Swiss Light Source of the
Paul Scherrer Institute on an EIGER X 16M or a PILATUS 6M detector (Dectris). Anomalous data
were collected at the bromine absorption edge (0.92 A˚). Data were integrated and scaled with XDS
(Kabsch, 2010) and further processed with CCP4 programs (Collaborative Computational Project,
1994). Structures were refined in Phenix (Adams et al., 2002) using the EcoDMT WT structure (PDB
ID 5M87) as starting model. The model was modified in COOT (Emsley and Cowtan, 2004) and
constraints for the refinement of the Br-BIT ligand were generated using the CCP4 program
PRODRG (Schu¨ttelkopf and van Aalten, 2004). Five percent of the reflections not used in refine-
ment were used to calculate Rfree. The final refinement statistics is reported in Table 2. The coordi-
nates of the EcoDMT-Br-BIT complex refined to data at 3.8 A˚ were deposited with the PDB under
accession code 6TL2.
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Modeling and Poisson-Boltzmann calculations
The electrostatic potential in the extracellular aqueous cavity harboring the inhibitor binding site was
calculated by solving the linearized Poisson–Boltzmann equation in CHARMM (Brooks et al., 1983;
Im et al., 1998) on a 150 A˚ 150 A˚  200 A˚ grid (1 A˚ grid spacing) followed by focusing on a 100 A˚
x 100 A˚ x 120 A˚ grid (0.5 A˚ grid spacing). Partial protein charges were derived from the CHARMM36
all-hydrogen atom force field. Hydrogen positions were generated in CHARMM, histidines were pro-
tonated. The protein was assigned a dielectric constant () of 2. Its transmembrane region was
embedded in a 30 A˚-thick slab ( = 2) representing the hydrophobic core of the membrane and two
adjacent 10 A˚-thick regions ( = 30) representing the headgroups. The membrane region contained
a 38 A˚-high and 22 A˚-wide aqueous cylinder ( = 80) covering the extracellular aqueous cavity and
was surrounded by an aqueous environment ( = 80). Calculations were carried out in the absence of
monovalent mobile ions in the aqueous regions. The homology model of human DMT1 was pre-
pared with the SWISS-MODEL homology modeling server (Biasini et al., 2014).
Reconstitution of EcoDMT into liposomes
EcoDMT WT and mutants were reconstituted using detergent destabilized liposomes according to
Geertsma et al. (2008). The liposomes were formed using the synthetic phospholipids POPE and
POPG (Avanti Polar lipids) at a w/w ratio of 3:1. The lipids where resuspended in 20 mM HEPES, pH
7.5, and 100 mM KCl after washing with diethylether and drying by exsiccation. Liposomes were
subjected to three freeze-thaw cycles and extruded through a 400 nm polycarbonate filter (Avestin,
LiposoFast-Basic) to form unilammellar vesicles. Triton X-100 was used to destabilize the liposomes
and the reconstitutions were performed at a protein to lipid ratio of 1:100 (w/w) for transport assays
and a protein to lipid ratio of 1:50 (w/w) to determine the orientation of the transporters in the lipo-
somes. After detergent removal by the successive addition of Bio-Beads SM-2 (Bio-Rad) over a
period of three days, proteoliposomes were harvested by centrifugation, resuspended in buffer con-
taining 20 mM HEPES, pH 7.5, and 100 mM KCl and stored in liquid nitrogen.
The orientation of the transporters in proteoliposomes was determined using a reconstitution of
EcoDMT-His10 in which the C-terminally Histidine-tag preceded by a 3C protease cleavage site has
not been cleaved prior to reconstitution. Initially, proteoliposomes (containing a total of 2 mg lipids)
were extruded using a 400 nm polycarbonate filter to generate unilammellar vesicles and split in two
equal aliquots. Purified 3C protease was subsequently added to the outside of one aliquot of the
proteoliposmes and incubated for 2 hr at room temperature. The external 3C protease was removed
by washing twice with 20 volumes of 20 mM HEPES, pH 7.5, and 100 mM KCl and the liposomes
were harvested by centrifugation. After removal of the protease, the liposomes were dissolved by
addition of DM at a detergent to lipid ration of 1.25:1 (w/w) with half of the samples incubated with
3C protease for 2 hr on ice. All 3C cleavage steps were performed with a large excess of protease
to ensure completion of the reaction. Control liposomes not treated with 3C protease at the differ-
ent steps were processed the same way. A sample of purified EcoDMT-His10 was used as control to
follow the removal of the His10-tag in a sample with unrestricted accessibility to the 3C cleavage
site. The final samples were analyzed by SDS-PAGE.
Fluorescence-based Mn2+ transport and inhibition assays
Proteoliposomes for the Mn2+ transport and inhibition assays were obtained by resuspension of
vesicles in buffer B containing 20 mM HEPES, pH 7.5, 100 mM KCl and 250 mM calcein (Invitrogen)
and subjection to three freeze-thaw cycles followed by extrusion through a 400 nm filter. Proteolipo-
somes were harvested by centrifugation and washed twice with 20 volumes of buffer B without Cal-
cein. The samples were subsequently diluted to 0.25 mg lipid ml–1 in buffer containing 20 mM
HEPES, pH 7.5 and 100 mM NaCl and varying concentrations of TMBIT, Br-BIT or oBr-BIT. Subse-
quently, 100 ml aliquots were placed in a black 96-well plate and after stabilization of the fluores-
cence signal, valinomycin (at a final concentration of 100 nM) and MnCl2 were added to start the
assay. Uptake of Mn2+ into liposomes was recorded by measuring the fluorescence change in a fluo-
rimeter (Tecan Infinite M1000, lex=492 nm/ lem=518 nm) in four-second intervals. As a positive con-
trol, Mn2+ ions were equilibrated by addition of the ionophore calcimycin (at a final concentration of
100 nM) (Invitrogen), which acts as a Mn2+/H+ exchanger at the end of the experiments. In presence
of TMBIT or oBr-BIT at concentrations higher than 50 mM, the fluorescence signal after addition of
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calcimycin did not reach the same low level as observed in absence of inhibitors, which suggests an
interference of the compounds with the activity of calcimycin at high concentrations. Initial transport
rates (DF min–1) were obtained by performing a linear regression of transport data obtained between
60 and 120 s after addition of valinomycin and MnCl2 and fitted to a Michaelis-Menten equation.
Kinetic data of WT and all mutants described in this study was measured in at least three indepen-
dent experiments.
Analysis of kinetic data
Kinetic data was fitted to a mixed enzyme inhibition model outlined below
(Scheme 1) (Copeland, 2005) with GraphPad Prism (GraphPad Software, San Diego, California USA,
www.graphpad.com):
Scheme 1. Mixed enzyme inhibition model.
This model assumes that the inhibitor (I) binds to the substrate free transporter (T) and to the
transporter-substrate complex (TM2+) with equilibrium constants Ki and Kii, respectively. Both equi-
librium constants can be obtained by a non-linear regression to Equation 2
v¼
Vmax S
Km  1þ I
Ki
  
þ S  1þ I
Kii
   withKii¼ a Ki (2)
For high values of a, the inhibitor preferentially binds to the substrate-free transporter and Equa-
tion 2 approaches a model for competitive inhibition. The resulting equilibrium constants obtained
for hDMT1 using a radioactive 55Fe2+ transport assay and for EcoDMT1 using an in vitro proteolipo-
some-based assay are summarized in Table 1.
Isothermal titration calorimetry
Isothermal titration calorimetry experiments were performed with a MicroCal ITC200 system (GE
Healthcare). The titrations of MnCl2 to TMBIT and Br-BIT were performed at 25˚C in 20 mM HEPES,
pH 7.5, and 100 mM KCl. The syringe was filled with 5 mM MnCl2 and sequential aliquots of 2 ml
were added to the sample cell filled with 0.4 mM TMBIT, Br-BIT, Ethylenediaminetetraacetic acid
(EDTA) or buffer. The titrations of Br-BIT to purified EcoDMT were performed at 6˚C in 20 mM
HEPES, pH 7.5, 150 mM and 0.04% (w/v) DDM. The syringe was filled with 1.8 mM or 2.5 mM Br-BIT
and sequential aliquots of 1.5–2 ml were added to the sample cell filled with ~50 mM or ~180 mM
EcoDMT WT, the mutant D51A or buffer. Data were analyzed using the Origin ITC analysis package
and the MicroCal ITC program Concat and errors on the reported KD values represent fitting errors.
The data were fit using models assuming one or two sets of binding sites. In case of 2.5 mM Br-BIT
in the syringe and ~180 mM EcoDMT in the cell, mainly the high affinity step saturating in the low
micromolar range is titrated. Therefore, the low affinity transition can be ignored and the resulting
reaction enthalpies were y-translated to zero to enable data analysis using a model assuming a single
set of binding sites. For each protein, similar results were obtained for at least two experiments from
independent protein preparations.
Data availability
The coordinates and structure factors of the EcoDMT-Br-BIT complex have been deposited in the
Protein Data Bank with the accession code 6TL2.
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Appendix 1
Supporting Information for Chemical Synthesis
Synthesis
All reagents for the synthesis of compounds 1–7 (Appendix 1—table 1) were purchased from
commercial sources depending on availability (Sigma Aldrich, TCI or Key organics) and were
used without further purification. Absolute ethanol was from VWR. Hexane, diethyl ether, ethyl
acetate, dichloromethane and methanol were purchased from Grogg Chemie and distilled
prior utilization. HPLC grade acetonitrile was purchased from Fisher scientific. Flash
chromatography purifications were performed with silica Gel 60 (Sigma, 0.040–0.063 nm, 230–
400 mesh ASTM). Low resolution mass spectra were obtained by electron spray ionization
(ESI-MS) in the positive mode on a Thermo Scientific LCQ Fleet. High resolution mass spectra
were obtained by electron spray ionization (HR-ESI-MS) in the positive mode recorded on a
Thermo Scientific LTQ Orbitrap XL. 1H and 13C-NMR spectra were measured on a Bruker
Avance 300 spectrometer (at 300 MHz and 75 MHz, respectively) or on a Bruker Avance II 400
spectrometer (at 400 MHz and 101 MHz, respectively) (Appendix 1—figures 1–7). 1H and 13C
chemical shifts are quoted relative to solvent signals, and resonance multiplicities are reported
as s (singlet), d (doublet), t (triplet), q (quartet), p (pentet), and m (multiplet); br = broad peak.
Compound purities were assessed by analytical reversed phase HPLC (RP-HPLC) at a detection
wavelength of 214 nm (Appendix 1—table 2). Analytical RP-HPLC was performed on a Dionex
Ultimate 3000 RSLC System (DAD-3000 RS Photodiode Array Detector) using a Dionex
Acclaim RSLC 120 column (C18, 3.0  50 mm, particle size 2.2 mm, 120 A˚ pore size) and a flow
rate of 1.2 ml min 1. Data were recorded and processed with Dionex Chromeleon
Management System (version 6.8) and Xcalibur (version 2.2, Thermo Scientific). Eluents for
analytical RP-HPLC were as follows: (A) milliQ-deionized water containing 0.05% TFA, (D)
HPLC-grade acetonitrile/milliQ-deionized water (9:1) containing 0.05% TFA. Conditions for
analytical RP-HPLC were as follows: in 2.2 min from 100% A to 100% D, then staying on 100%
D (method A) in 7.5 min from 100% A to 100% D, then staying on 100% D (method B), GC
analyses were carried out on a Macherey-Nagel Optima delta-3–0.25 mm capillary column (20
m, 0.25 mm); carrier gas: He 1.4 ml min 1; injector: 220˚C split mode; detector: FID 280˚C, H2
35 ml min 1, air 350 ml min 1. GC–MS analyses were performed on an apparatus equipped
with a quadrupole mass analyzer using electron impact (70 eV) fitted with a Macherey-Nagel
Optima delta-3–0.25 mm capillary column (20 m, 0.25 mm); carrier gas: He 1.4 ml min 1;
injector: 220˚C split mode.
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Appendix 1—figure 1. Spectroscopic characterization of compound 1. 1H NMR spectrum of
the purified compound is shown on the top, 13C NMR spectrum on the bottom. Chemical
shifts are displayed and listed in the respective synthesis section.
Manatschal et al. eLife 2019;8:e51913. DOI: https://doi.org/10.7554/eLife.51913 26 of 36
Research article Biochemistry and Chemical Biology Structural Biology and Molecular Biophysics
Appendix 1—figure 2. Spectroscopic characterization of compound 2. 1H NMR spectrum of
the purified compound is shown on the top, 13C NMR spectrum on the bottom. Chemical
shifts are displayed and listed in the respective synthesis section.
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Appendix 1—figure 3. Spectroscopic characterization of compound 3. 1H NMR spectrum of
the purified compound is shown on the top, 13C NMR spectrum on the bottom. Chemical
shifts are displayed and listed in the respective synthesis section.
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Appendix 1—figure 4. Spectroscopic characterization of compound 4. 1H NMR spectrum of
the purified compound is shown on the top, 13C NMR spectrum on the bottom. Chemical
shifts are displayed and listed in the respective synthesis section.
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Appendix 1—figure 5. Spectroscopic characterization of compound 5. 1H NMR spectrum of
the purified compound is shown on the top, 13C NMR spectrum on the bottom. Chemical
shifts are displayed and listed in the respective synthesis section.
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Appendix 1—figure 6. Spectroscopic characterization of compound 6. 1H NMR spectrum of
the purified compound is shown on the top, 13C NMR spectrum on the bottom. Chemical
shifts are displayed and listed in the respective synthesis section.
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Appendix 1—figure 7. Spectroscopic characterization of compound 7. 1H NMR spectrum of
the purified compound is shown on the top, 13C NMR spectrum on the bottom. Chemical
shifts are displayed and listed in the respective synthesis section.
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Appendix 1—table 1. Compound properties.
Compound Smile
IC50
(hDMT1)
(mM)
IC50
(hDMT1-
S476V)
(mM)
IC50
(hDMT1-
N520L)
(mM)
IC50
(hDMT1-
F523A)
(mM)
1 BrC1 = CC = C(C(C = CC(Br)
=C2CSC(N)=N)=C2O3)
C3 = C1CSC(N)=N
1.24  0.23 11.3  0.3 2.0  0.4 2.9  0.9
2 CC1 = C(CSC(N)=N)C(C)=CC(C)
=C1CSC(N)=N
0.35  0.04 36.1  8.0 21.7  6.9 82.9  5.3
3 NC(SCC1 = C(CC)C = C(CC)C
(CSC(N)=N)=C1 CC)=N
0.27  0.07 32.1  6.3 13.7  3.9 17.8  7.0
4 BrC1 = CC(CSC(N)=N)=CC(CSC
(N)=N)=C1
4.66  0.4 47.6  6.8 - 17.3  0.5
5 NC(SCC1 = CC = CC(CSC(N)
=N)=C1 Br)=N
2.3  0.25
6 NC(SCC1 = CC = CC
(CSC2 = NCCN2)=C1 Br)=N
8.13  0.47
7 BrC1 = C(CSC2 = NCCN2)
C = CC = C1CSC3 = NCCN3
161  24
Definition of method 1
Brominated intermediate (one eq) and thiourea (two eq) were dissolved in ethanol. The
solution was stirred at 80˚C overnight and then cooled down to room temperature. Ethanol
was removed except 1 ml which was kept. Hexane was added, and the precipitate was
filtered and dried in vacuo (Chafeev et al., 2008).
Synthesis of (3,7-dibromodibenzo[b,d]furan-4,6-diyl)bis
(methylene) dicarbamimidothioate, TFA salt (1 - Br-
DBFIT)
Compound 1 was synthesized following method 1 using 10 (169 mg, 0.33 mmol,1.0 eq) and
thiourea (57 mg, 0.75 mmol, 2.3 eq) in ethanol (9 ml). The precipitate was washed with
diethyl ether/Ethyl acetate (50/50) and then purified by preparative HPLC (gradient from 85/
15 A/D to 45/55 A/D in 18 min, tR = 31% D) to afford 1 (120 mg, 0.33 mmol, 50%) as an off-
white solid (Appendix 1—figure 1).
RP-UPLC: tR = 3.27 min (method B).
1H NMR (400 MHz, DMSO): d 9.38 (s, 6H, NH + NH2),
8.17 (2H, d, J = 8.3 Hz), 7.80 (2H, d, J = 8.3 Hz), 4.93 (4H, s, CH2).
13C NMR (400 MHz,
DMSO): d 168.6, 154.2, 128.6 (CHar), 123.3, 123.2, 123.1 (CHar), 119.0, 29.9 (CH2). HR-MS
calculated for C16H15Br2N4OS2: m/z 500.9049, m/z found 500.9053.
Synthesis of (2,4,6-trimethyl-1,3-phenylene)bis
(methylene) dicarbamimidothioate, TFA salt (2 -TMBIT)
Compound 2 was synthesized following method 1 using 11 (200 mg, 0.65 mmol, one eq) and
thiourea (109 mg, 1.4 mol, 2.2 eq) in ethanol (10 ml). The residue was purified by preparative
HPLC (gradient from 95/5 A/D to 75/25 A/D in 18 min, tR = 16% D) to afford 2 (215 mg, 0.41
mmol, 62%) as a white solid (Appendix 1—figure 2).
RP-UPLC: tR = 1.31 min (method A).
1H NMR (400 MHz, DMSO): d 9.41 (6H, s, NH), 7.03
(1H, s, CHar), 4.50 (4H, s, CH2), 2.40 (3H, s, CH3), 2.33 (6H, s, CH3).
13C NMR (101 MHz,
DMSO): d 169.9, 158.4, 138.1, 137.8, 130.7 (CHar), 127.6, 30.6 (CH2), 19.3 (CH3), 15.1 (CH3).
HR-MS calculated for C13H21N4S2: m/z 297.1202, m/z found 287.1205.
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Synthesis of (2,4,6-triethyl-1,3-phenylene)bis(methylene)
dicarbamimidothioate, TFA salt (3 - TEBIT)
Compound 3 was synthesized following method 1 using 12 (42 mg, 0.1 mmol, one eq) and
thiourea (16 mg, 0.21 mmol, 2.2 eq) in ethanol (4 ml). The residue was purified by
preparative HPLC (gradient from 95/5 A/D to 75/25 A/D in 18 min, tR = 24% D) to afford 3
(52 mg, 0.09 mmol, 94%) as a white solid (Appendix 1—figure 3).
RP-UPLC: tR = 1.52 min (method A).
1H NMR (300 MHz, DMSO): d 9.26 (6H, s, NH + NH2),
7.08 (1H, s, Har), 4.45 (4H, s, CH2), 2.71 (6H, m, CH2CH3), 1.21 (9H, t, J = 7.5 Hz, CH3).
13C
NMR (101 MHz, DMSO): d 169.5, 144.6, 143.8, 127.8 (CHar), 126.1, 29.5 (CH2), 25.3 (CH2),
22.3 (CH2), 16.5 (CH3), 15.4 (CH3). HR-MS calculated for C16H27N4S2: m/z 339.1672, m/z
found 339.1670.
Synthesis of (5-bromo-1,3-phenylene)bis(methylene)
dicarbamimidothioate, HBr salt (4 - Br-BIT)
Compound 4 was synthesized following method 1 using 1-Bromo-3,5-bis(bromomethyl)
benzene (200 mg, 0.58 mmol, one eq) and thiourea (98 mg, 1.3 mmol, 2.2 eq) in ethanol (10
ml). The precipitate was washed with EtOAc and dried in vacuo to afford 4 (262 mg, 0.53
mmol, 90%) as a white solid (Appendix 1—figure 4).
RP-UPLC: tR = 1.25 min (method A).
1H NMR (400 MHz, DMSO): d 9.13 (s, 6H), 7.63 (d,
J = 1.2 Hz, 2H), 7.46 (s, 1H), 4.50 (s, 4H). 13C NMR (101 MHz, DMSO): d 168.5, 138.5, 131.2
(CHar), 128.5 (CHar), 121.8, 33.2 (CH2). HR-MS calculated for C10H14BrN4S2: m/z 332.9838, m/
z found 332.9836.
Synthesis of (2-bromo-1,3-phenylene)bis(methylene)
dicarbamimidothioate, TFA salt (5 - oBr-BIT)
Compound 5 was synthesized following method 1 using 2-bromo-1,3-bis(bromomethyl)-
benzene (158 mg, 0.46 mmol, one eq) and thiourea (79 mg, 1.05 mmol, 2.3 eq) in ethanol (8
ml). The residue was purified by preparative HPLC (gradient from 100/0 A/D to 85/15 A/D in
18 min, tR = 4% D) to afford 5 (70 mg, 0.13 mmol, 27%) as a white solid (Appendix 1—
figure 5).
RP-UPLC: tR = 1.18 min (method A).
1H NMR (400 MHz, DMSO): d 9.36 (6H, s, NH + NH2),
7.59 (2H, d, J = 7.6 Hz, Har), 7.47 (1H, t, J = 7.2 Hz, Har), 4.60 (4H, s, CH2).
13C NMR (101
MHz, DMSO): d 168.9, 135.5, 131.3 (CHar), 128.5 (CHar), 126.5, 35.8 (CH2). HR-MS calculated
for C10H14BrN4S2: m/z 332.9838, m/z found 332.9842.
Synthesis of 2-bromo-3-(((4,5-dihydro-1H-imidazol-2-yl)
thio)methyl)benzyl carbamimidothioate, TFA salt
(compound 6)
2-bromo-1,3-bis(bromomethyl)-benzene (150 mg, 0.44 mmol, one eq) was dissolved in
ethanol (8 mL) before the addition of thiourea (34 mg, 0.45 mmol, one eq). The solution was
stirred at 40˚C overnight and then cooled down to room temperature. Ethanol was removed
and the residue was purified by column chromatography on silica gel (DCM/MeOH 90/10).
The product was dissolved in ethanol (8 ml) and imidazolidine-2-thione (47 mg, 0.44 mmol,
one eq) was added. The solution was stirred at 40˚C overnight. The solution was cooled
down to room temperature and ethanol was removed except 1 ml which was kept. Hexane
was added and the precipitate was filtered and dried in vacuo. The product was purified by
preparative HPLC (gradient from 100% A to 90/10 A/D in 28 min, tR = 7% D) to afford 6 (73
mg, 0.13 mmol, 28%) as a white solid (Appendix 1—figure 6).
RP-UPLC: tR = 1.21 min (method A).
1H NMR (300 MHz, MeOD): d 7.58 (2H, d, J = 7.6 Hz,
Har), 7.47 (1H, t, J = 7.5 Hz, Har), 4.67 (2H, s, CH2), 4.63 (2H, s, CH2), 4.00 (4H, s, CH2).
13C
NMR (101 MHz, MeOD): d 172.0, 170.9, 136.6, 136.2, 133.1 (CHar), 132.9 (CHar), 129.9
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(CHar), 128.0, 6, 46.8 (CH2), 37.9 (CH2), 37.8 (CH2). HR-MS calculated for C12H16BrN4S2: m/z
358.9994, m/z found 358.9995.
Synthesis of 2,2’-(((2-bromo-1,3-phenylene)bis
(methylene))bis(sulfanediyl))bis(4,5-dihydro-1H-
imidazole), TFA salt (compound 7)
Compound 7 was synthetized following method 1 using 2-bromo-1,3-bis(bromomethyl)-
benzene (165 mg, 0.48 mmol, one eq) and imidazolidine-2-thione (111 mg, 1.1 mmol, 2.2 eq)
in ethanol (8 ml). The residue was purified by preparative HPLC (gradient from 100% A to
80/20 A/D in 28 min, tR = 8% D) to afford 7 (141 mg, 0.23 mmol, 48%) as a white solid
(Appendix 1—figure 7).
RP-UPLC: tR = 1.17 min (method A).
1H NMR (300 MHz, DMSO): d 7.60 (2H, d, J = 7.5 Hz,
Har), 7.48 (1H, t, J = 7.3 Hz, Har), 4.67 (4H, s, CH2), 4.00 (8H, s, CH2).
13C NMR (101 MHz,
MeOD): d 170.9, 136.3, 133.0 (CHar), 130.0 (CHar), 128.0, 46.8 (CH2), 37.9 (CH2). HR-MS
calculated for C14H18BrN4S2: m/z 385.0151, m/z found 385.0142.
Synthesis of 4,6-dimethyldibenzo[b,d]furan (8)
In a three-necks flask, dibenzofuran (2.0 g, 11.9 mmol, one eq) was dissolved in dry diethyl
ether (100 ml) under argon atmosphere. The temperature was cooled down to – 78˚C before
the addition of TMEDA (4.3 ml, 29.5 mmol, 2.6 eq). sec BuLi (21.2 ml, 1.4 M, 29.7 mmol, 2.5
eq) was added slowly (dropwise). The mixture was stirred 16 hr and allowed to heat at room
temperature during the night. Iodomethane (3.80 ml, 61.0 mmol, 5.0 eq) was added. The
reaction mixture was stirred at room temperature for 20 hr. Then NH4Cl sat (70 ml) was
added to quench the reaction. The product was extracted with diethyl ether (3 times 100 ml).
The organic layers were combined, dried over Na2SO4, filtered and concentrated. The
residue was recrystallized from methanol to afford 8 (846 mg, 4.3 mmol, 36%) as a white
solid (Chafeev et al., 2008).
1H NMR (400 MHz, CDCl3): d 7.75 (2H, dd, J = 6.4, 2.6 Hz, Har), 7.25–7.20 (2H, m, Har),
2.62 (6H, s, CH3).
13C NMR (75 MHz, CDCl3): d 155.1, 128.0 (CHar), 124.2, 122.6 (CHar),
122.0, 118.2 (CHar), 15.4 (CH3).
Synthesis of 3,7-dibromo-4,6-dimethyldibenzo[b,d]furan
(9)
8 (200 mg, 1.0 mmol, one eq) was dissolved in acetic acid (3 ml). Br2 (0.11 ml, 2.1 mmol, 2.1
eq) was added. The mixture was stirred at room temperature overnight. Br2 (0.4 ml, 0.82
mmol, 0.8 eq) was added and the solution was stirred at room temperature for 24 hr. Water
was added. A precipitate appeared, was filtered and kept. DCM was added in the filtrate.
Product was extracted with DCM. Organic layers were combined, washed with water, dried
over Na2SO4 and concentrated. All compound was recrystallized from ethyl acetate and then
purified by flash column chromatography on silica gel (Hexane) to afford 9 (330 mg, 1.1
mmol, 65%) as an off-white solid (Chafeev et al., 2008).
RP-GCMS: tR = 9.50 min (from 50˚C to 280˚C in 8 min, then stay at 280˚C).
1H NMR (300
MHz, CDCl3): d 7.58 (2H, d, J = 8.4 Hz), 7.50 (2H, d, J = 8.3 Hz), 2.64 (s, 6H).
13C NMR (101
MHz, CDCl3): d 155.3, 127.2 (CHar), 123.3, 123.0, 122.9, 118.8 (CHar), 15.7 (CH3).
Synthesis of 3,7-dibromo-4,6-bis(bromomethyl)dibenzo
[b,d]furan (10)
9 (196 mg, 0.56 mmol, 1.0 eq) and NBS (214 mg, 1.2 mmol, 2.2 eq) were dissolved in CCl4
(41 ml) under argon. Benzoyl peroxide (one spatula) was added. The mixture was stirred at
60˚C overnight. NBS (212 mg, 1.2 mmol, 2.2 eq) and benzoyl peroxide (1.5 spatula) were
added. The mixture was stirred at 60˚C overnight before cooled down to 0˚C. The white
precipitate was filtered, and the solvent was removed. The residue was recrystallized from
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Hexane/Ethyl acetate (50:50) to afford 10 (134 mg, 0.56 mmol, 47%) as an off-white solid
(Chafeev et al., 2008).
1H NMR (300 MHz, CDCl3): d 7.73 (2H, d, J = 8.3 Hz), 7.60 (2H, d, J = 8.3 Hz), 5.00 (4H, s,
CH2).
13C NMR (101 MHz, CDCl3): d 154.9, 128.4 (CHar), 123.6, 123.6, 122.8, 121.8 (CHar),
26.0 (CH2).
Synthesis of 2,4-bis(bromomethyl) 1,3,5-
trimethylbenzene (11)
To a suspension of paraformaldehyde (150 mg, 5.0 mmol, two eq) in acetic acid (2.5 ml),
mesitylene (0.35 ml, 2.5 mmol, one eq) was added. HBr (1 ml, 31% in acetic acid) was added
quickly. The mixture was stirred at 80˚C for 8 hr. Water (10 ml) was added and the white
precipitate was filtered and dried in vacuo. The product was purified by flash
chromatography on silica gel (Hexane) to afford 11 (530 mg, 1.7 mmol, 69%) as a white solid
(Van der Made and Van der Made, 1993).
1H NMR (400 MHz, CDCl3): d 6.90 (s, 1H), 4.57 (s, 4H), 2.45 (s, 3H), 2.38 (s, 6H).
13C NMR
(101 MHz, CDCl3): d 138.2, 137.3, 132.8, 130.9 (CHar), 29.9 (CH2), 19.6 (CH3), 14.8 (CH3).
Synthesis of 2,4-bis(bromomethyl) 1,3,5-triethylbenzene
(12)
To a suspension of paraformaldehyde (80 mg, 2.7 mmol, two eq) in acetic acid (2.5 ml),
1,3,5-triethylbenzene (0.25 ml, 1.3 mmol, one eq) was added. HBr (0.7 ml, 31% in acetic acid)
was added quickly. The mixture was stirred at 80˚C for 8 hr. Water (10 ml) was added and
product was extracted three times with EtOAc. The combined organic layers were dried over
Na2SO4 and concentrated. The residue was purified by flash chromatography on silica gel
(Hexane) to afford 12 (42 mg, 0.1 mmol, 7%) as a white solid (Van der Made and Van der
Made, 1993).
RP-UPLC: tR = 1.91 min (method A).
1H NMR (400 MHz, CDCl3): d 6.97 (1H, s, Har), 4.60
(4H, s, CH2), 2.94 (2H, q, J = 7.6 Hz, CH2CH3), 2.77 (4H, q, J = 7.6 Hz, CH2CH3), 1.32 (9H, m,
CH3).
13C NMR (101 MHz, CDCl3): d 144.9, 143.6, 131.5, 127.7 (CHar), 28.7 (CH2), 26.0 (CH2),
22.5 (CH2), 15.9 (CH3), 15.1 (CH3).
Appendix 1—table 2. HPLC Purity of final compounds.
Compound Retention time Purity [%] HPLC method*
1 3.27 min 99 B
2 1.31 min 99 A
3 1.52 min 99 A
4 1.25 min 99 A
5 1.18 min 99 A
6 1.21 min 99 A
7 1.17 min 99 A
*Method A: in 2.2 min from 100% A to 100% D, then staying on 100% D. Method B: in 7.5 min
from 100% A to 100% D, then staying on 100% D.
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